Nevertheless, our findings that an increase of FGF21 by CO improves metabolic dysfunction suggest that a low-dose application of CO may represent a potential therapeutic strategy for the amelioration of metabolic diseases. This evidence concerns the gene FGF21 and metabolic disease.